Aduro Biotech

Aduro Biotech is an immunotherapy company focused on the discovery, development and commercialization of therapies for the treatment of patients with diseases, including cancer. The company's primary technologies related to the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand pathways have a pipeline of clinical candidates including ADU-S100 (MIW815), ADU-S100 with spartalizumab, ADU-S100 with ipilimumab, ADU-S100 with anti-PD-1, cGAS-STING pathway inhibitor program, and BION-1301. The company's other programs consist of Anti-CD27 Antibody, which is a co-stimulatory receptor expressed on different immune cells, such as T-lymphocytes and NK cells.
  • TickerADRO
  • ISINUS00739L1017
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

Jonathan Moreland

InsiderInsights Daily Ratings Report: September 17, 2019

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ValuEngine Rating and Forecast Report for ADRO

ResearchPool Subscriptions

Get the most out of your insights

Get in touch